Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–9. https://doi.org/10.1126/science.1082504.

Article  CAS  PubMed  Google Scholar 

Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798–811. https://doi.org/10.1038/sj.onc.1209608.

Article  CAS  PubMed  Google Scholar 

Messmer MN, Snyder AG, Oberst A. Comparing the effects of different cell death programs in tumor progression and immunotherapy. Cell Death Differ. 2019;26:115–29. https://doi.org/10.1038/s41418-018-0214-4.

Article  PubMed  Google Scholar 

Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232:123–38. https://doi.org/10.1016/j.canlet.2005.01.041.

Article  CAS  PubMed  Google Scholar 

Riggins RB, Bouton AH, Liu MC, Clarke R. Antiestrogens, aromatase inhibitors, and apoptosis in breast cancer. Vitam Horm. 2005;71:201–37. https://doi.org/10.1016/S0083-6729(05)71007-4.

Article  CAS  PubMed  Google Scholar 

Saleh K, Daste A, et al. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2019;121:123–9. https://doi.org/10.1016/j.ejca.2019.08.026.

Article  CAS  PubMed  Google Scholar 

Birkhauser FD, et al. Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J. 2013;19:189–96. https://doi.org/10.1097/PPO.0b013e318292e8a4.

Article  CAS  PubMed  Google Scholar 

Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9. https://doi.org/10.1136/jitc-2021-002478.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122–50. https://doi.org/10.2967/jnumed.108.057307.

Article  CAS  Google Scholar 

Choi H, Charnsangavej C, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic Gastrointestinal stromal tumor treated at a single institution with Imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9. https://doi.org/10.1200/JCO.2006.07.3049.

Article  PubMed  Google Scholar 

Berz AM, Dromain C, Vietti-Violi N, Boughdad S, Duran R. Tumor response assessment on imaging following immunotherapy. Front Oncol. 2022;12:982983. https://doi.org/10.3389/fonc.2022.982983.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tseng J, Dunnwald LK, et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med. 2004;45:1829–37.

CAS  PubMed  Google Scholar 

Roe K, Aleksandersen TB, Kristian A, et al. Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol. 2010;49:914–21. https://doi.org/10.3109/0284186X.2010.498831.

Article  PubMed  Google Scholar 

Hicks RJ, Mac Manus MP, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys. 2004;60:412–8. https://doi.org/10.1016/j.ijrobp.2004.03.036.

Article  PubMed  Google Scholar 

Pugachev A, Ruan S, et al. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005;62:545–53. https://doi.org/10.1016/j.ijrobp.2005.02.009.

Article  CAS  PubMed  Google Scholar 

Kashyap D, Garg VK, Goel N. Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis. Adv Protein Chem Struct Biol. 2021;125:73–120. https://doi.org/10.1016/bs.apcsb.2021.01.003.

Article  CAS  PubMed  Google Scholar 

Buchholz TA, Davis DW, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J. 2003;9:33–41. https://doi.org/10.1097/00130404-200301000-00007.

Article  CAS  PubMed  Google Scholar 

De Saint-Hubert M, Bauwens M, Verbruggen A, Mottaghy FM. Apoptosis imaging to monitor cancer therapy: the road to fast treatment evaluation? Curr Pharm Biotechnol. 2012;13:571–83. https://doi.org/10.2174/138920112799436320.

Article  PubMed  Google Scholar 

Vangestel C, Peeters M, Mees G, Oltenfreiter R, Boersma HH, Elsinga PH, et al. In vivo imaging of apoptosis in oncology: an update. Mol Imaging. 2011;10:340–58. https://doi.org/10.2310/7290.2010.00058.

Article  CAS  PubMed  Google Scholar 

Chen DL, Engle JT, Griffin EA, Miller JP, Chu W, Zhou D, et al. Imaging caspase-3 activation as a marker of apoptosis-targeted treatment response in cancer. Mol Imaging Biol. 2015;17:384–93. https://doi.org/10.1007/s11307-014-0802-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shen B, Jeon J, Palner M, Ye D, Shuhendler A, Chin FT, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-triggered nanoaggregation probe. Angew Chem Int Ed Engl. 2013;52:10511–4. https://doi.org/10.1002/anie.201303422.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beroske L, Van den Wyngaert T, Stroobants S, Van der Veken P, Elvas F. Molecular imaging of apoptosis: the case of Caspase-3 radiotracers. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22083948.

Nguyen QD, Lavdas I, et al. Temporal and Spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013;19:3914–24. https://doi.org/10.1158/1078-0432.CCR-12-3814.

Article  CAS  PubMed  Google Scholar 

Nguyen QD, Smith G, et al. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled Isatin sulfonamide. Proc Natl Acad Sci U S A. 2009;106:16375–80. https://doi.org/10.1073/pnas.0901310106.

Article  PubMed  PubMed Central  Google Scholar 

Glaser M, Goggi J, et al. Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation. Bioorg Med Chem Lett. 2011;21:6945–9. https://doi.org/10.1016/j.bmcl.2011.10.001.

Article  CAS  PubMed  Google Scholar 

Witney TH, Fortt R, Aboagye EO. Preclinical assessment of carboplatin treatment efficacy in lung cancer by 18F-ICMT-11-positron emission tomography. PLoS ONE. 2014;9:e91694. https://doi.org/10.1371/journal.pone.0091694.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Challapalli A, Kenny LM, et al. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med. 2013;54:1551–6. https://doi.org/10.2967/jnumed.112.118760.

Article  CAS  PubMed  Google Scholar 

Van de Wiele C, Ustmert S, et al. Apoptosis imaging in oncology by means of positron emission tomography: A review. Int J Mol Sci. 2021;22. https://doi.org/10.3390/ijms22052753.

Dubash SR, Merchant S, et al. Clinical translation of [(18)F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer. Eur J Nucl Med Mol Imaging. 2018;45:2285–99. https://doi.org/10.1007/s00259-018-4098-9.

Article  CAS  PubMed  PubMed Central  Google Scholar